Gregory McKee has been appointed president and CEO of Victoria-based Stressgen Biotechnologies Corp, replacing Dan Korpolinski. The move comes after Stressgen withdrew its preliminary prospectus for a common share offering and a decision to sell its bioreagents business to a US firm (see New Briefs). Prior to his appointment, McKee was Stressgen’s chief financial officer and VP corporate development. Prior to joining Stressgen, he was senior director corporate development at Valentis Inc, San Francisco, and held several management positions with Genzyme Corp. McKee holds an MBA and MA from the Univ of Pennsylvania and a BA in economics from the Univ of Washington…